Megestrol Acetate Suspension
FDA Label NDC 24979-041

32 label sections · Submitted to the FDA by Upsher-smith Laboratories, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Upsher-smith Laboratories, Llc for the product Megestrol Acetate (NDC 24979-041). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 testing prior to megestrol acetate oral suspension administration, 2.2 dosing and administration, 3 dosage forms and strengths, 4 contraindications, 5.1 general, 5.2 fetal toxicity, 5.3 adrenal insufficiency, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.